Metformin-mechanisms of its glycemia-reducing effect

Area of Science:

• Endocrinology
• Metabolism
• Pharmacology

Background:

• Metformin is a first-line oral treatment for type 2 diabetes.
• Its precise glucose-lowering mechanisms remain incompletely understood.
• Known effects include improved glucose disposal and reduced hepatic gluconeogenesis.

Purpose of the Study:

• To elucidate the multifaceted mechanisms of metformin's glucose-lowering effects.
• To explore hepatic, skeletal muscle, and intestinal actions of metformin.
• To consolidate current understanding of metformin's impact on glucose metabolism.

Main Methods:

• Review of clinical, animal, and cellular studies on metformin's action.
• Analysis of proposed mechanisms involving AMP-activated protein kinase (AMPK) and mitochondrial complex I.
• Investigation of intestinal effects, including glucose absorption and GLP-1 secretion.

Main Results:

• Metformin reduces hepatic gluconeogenesis, potentially via AMPK or mitochondrial inhibition.
• It enhances glucose disposal in skeletal muscle, possibly through AMPK activation and anti-inflammatory effects.
• Intestinal mechanisms include inhibited glucose absorption and stimulated glucagon-like peptide-1 (GLP-1) secretion, impacting the gut-brain-liver axis.

Conclusions:

• Metformin's glucose-lowering effect is multifactorial, involving the gut, liver, and skeletal muscle.
• Inhibition of mitochondrial complex I is a key mechanism across different organs.
• Intestinal actions and stimulation of the gut-liver-brain axis are increasingly recognized as significant contributors.